Volrustomig + Cisplatin + Carboplatin + Paclitaxel
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
Trial Timeline
Aug 22, 2024 → Nov 30, 2028
NCT ID
NCT06535607About Volrustomig + Cisplatin + Carboplatin + Paclitaxel
Volrustomig + Cisplatin + Carboplatin + Paclitaxel is a phase 2 stage product being developed by AstraZeneca for Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06535607. Target conditions include Cervical Cancer, Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06535607 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cervical Cancer